Adipokines of Epicardial Adipose Tissue and Atherosclerosis of Coronary Arteries

Coronary Atherosclerosis Clinical Trial

Official title:

The Role of Adipokines Secreted by Epicardial Adipose Tissue in the Atherosclerosis of Coronary Arteries

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03322332
• Other study ID #: 741
• Status: Recruiting
• Phase: N/A
• First received: October 23, 2017
• Last updated: October 23, 2017
• Start date: October 23, 2017
• Est. completion date: January 22, 2018

Study information

• Verified date: October 2017
• Source: University Hospital, Ioannina
• Contact: Eustratios Apostolakis, Professor
• Phone: 0030 2651099679
• Email: stratisapostolakis[@]yahoo.gr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of the study is to investigate whether the expression and production of adipokines secreted by the epicardial adipose tissue correlate with the degree of coronary atherosclerosis.

Description:

The aim of the study is to investigate whether the expression and production of four adipokines [adiponectin, omenin-1, resistin and retinol binding protein-4 (RBP4)] secreted by the epicardial adipose tissue correlate with the degree of coronary atherosclerosis. Specifically, this study aims to investigate whether the expression and production of these adipokines is different between two sites of the heart, that are perfused by coronary arteries with different degrees of stenosis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 160
• Est. completion date: January 22, 2018
• Est. primary completion date: January 15, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1) Individuals undergoing cardiac surgery

Exclusion Criteria:

• Age < 18 years

• HbA1c > 7.0%

• Any change of antidiabetic medication the previous 3 months before the surgery

• GFR < 60 mL/min/1.73 m2

• Liver disease

• Cancer

• Non-treated hyperthyroidism or hypothyroidism

• Autoimmune disease

• Infection

• Any change in body weight at least 5% the previous 3 months before surgery

• Significant dehydration.

• Taking any of the following drugs the previous 3 months before surgery: hormones, antiobesity drugs

Related Conditions & MeSH terms

• Adipokines
• Atherosclerosis
• Coronary Artery Disease
• Coronary Atherosclerosis
• Myocardial Ischemia

Locations

Country	Name	City	State
Greece	University Hospital of Ioannina	Ioánnina

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Ioannina

Country where clinical trial is conducted

Greece, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Association between coronary artery disease and epicardial adipokines	Comparison of the mRNA and protein production of four adipokines [adiponectin, omentin-1, resistin, retinol binding protein-4(RBP4)] from the epicardial adipose tissue between the territories that are supplied by LAD and RCA. This comparison will be performed in the following clusters of groups: Cluster 1: NonDM-0 and DM-0 (comparison between territories that are supplied by non-stenosed coronary arteries); Cluster 2: NonDM-LR and DM-LR (comparison between territories that are supplied by stenosed coronary arteries); Cluster 3: NonDM-L, NonDM-R, DM-L and DM-R (comparison between a territory that is supplied by stenosed coronary artery and another territory that is supplied by non-stenosed coronary artery)	Baseline measurement
Secondary	Impact of diabetes on epicardial adipokines	Comparison of the mRNA and protein production of four adipokines (adiponectin, omentin-1, resistin, RBP4) from the epicardial adipose tissue of the territory that is supplied by LAD or RCA between the following groups: NonDM-0 vs DM-0; NonDM-L vs DM-L; NonDM-R vs DM-R; NonDM-LR vs DM-LR	Baseline measurement